Innovative Eyewear, Inc. (NASDAQ:LUCY – Get Free Report) major shareholder Vladimir Galkin purchased 297,443 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were bought at an average price of $8.91 per share, with a total value of $2,650,217.13. Following the acquisition, the insider now directly owns 785,573 shares of the company’s stock, valued at approximately $6,999,455.43. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Vladimir Galkin also recently made the following trade(s):
- On Tuesday, September 17th, Vladimir Galkin sold 258,483 shares of Innovative Eyewear stock. The stock was sold at an average price of $7.27, for a total value of $1,879,171.41.
Innovative Eyewear Trading Up 11.9 %
Innovative Eyewear stock traded up $1.08 during trading on Tuesday, hitting $10.13. 389,677 shares of the company were exchanged, compared to its average volume of 1,205,103. The business’s 50 day moving average is $5.06 and its 200 day moving average is $6.55. Innovative Eyewear, Inc. has a 52 week low of $3.26 and a 52 week high of $27.20.
Innovative Eyewear Company Profile
Innovative Eyewear, Inc develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice.
Recommended Stories
- Five stocks we like better than Innovative Eyewear
- 3 Warren Buffett Stocks to Buy Now
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- The How and Why of Investing in Gold Stocks
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is MarketRank™? How to Use it
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Innovative Eyewear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovative Eyewear and related companies with MarketBeat.com's FREE daily email newsletter.